Whither antibacterial drug discovery?

Drug Discovery Today

Volumn 13, Issue 7-8, 2008, Pages 279-280

  Projan, Steven J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BIOINFORMATICS; CHEMOTHERAPY; DECISION MAKING; DRUG INDUSTRY; DRUG MECHANISM; EDITORIAL; FUNDING; HOSPITAL; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROORGANISM; MORTALITY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOME, BACTERIAL; HUMANS;

EID: 41649102800     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.03.010     Document Type: Editorial

References (8)

1. Rice L.B. Do we really need new anti-infective drugs?. Curr. Opin. Pharmacol. 3 (2003) 459-463
2. Projan S.J., and Bradford P.A. Late stage antibacterial drugs in the clinical pipeline. Curr. Opin. Microbiol. 10 (2007) 1-6
3. Projan S.J., and Shlaes D.M. Antibacterial drug discovery: is it all downhill from here?. Clin. Microbiol. Infect. 10 (2004) 18-22
4. Payne D.J., et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 (2007) 29-40
5. Projan S.J. (Genome) size matters. Antimicrob. Agents Chemother. 51 (2007) 1133-1134
6. Klevens R.M., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
7. Blount K.F., and Breaker R.R. Riboswitches as antibacterial drug targets. Nat. Biotechnol. 24 (2006) 1558-1564
8. Brotz-Oesterhelt H., et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11 (2005) 1082-1087